OGN

Dopo l'orario di chiusura: 16.41 -0.05 -0.30%

Organon Co (OGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Storia dei dividendi

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Organon Co Stock (OGN) Company Profile

Healthcare (1182)

551-430-6000

30 HUDSON STREET, JERSEY CITY

Prossima data di guadagno

Ultimi documenti SEC

OGN's Discussions on Twitter

Organon Co Stock (OGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-09-06	Downgrade	JP Morgan	Neutral → Underweight
2023-11-03	Downgrade	Goldman	Buy → Neutral
2023-09-21	Iniziato	Barclays	Overweight
2023-03-16	Iniziato	Raymond James	Outperform
2022-10-14	Downgrade	BofA Securities	Neutral → Underperform
2022-09-06	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-08-05	Downgrade	BofA Securities	Buy → Neutral
2022-04-27	Iniziato	Goldman	Buy
2022-04-06	Ripresa	Morgan Stanley	Equal-Weight
2021-10-07	Iniziato	Piper Sandler	Neutral
2021-09-01	Iniziato	BofA Securities	Buy
2021-07-22	Iniziato	Citigroup	Buy
2021-06-15	Iniziato	JP Morgan	Neutral
2021-06-11	Iniziato	Morgan Stanley	Equal-Weight
2021-06-10	Iniziato	Evercore ISI	Outperform

Mostra tutto

Organon Co Borsa (OGN) Ultime notizie

Organon Co Azioni (OGN) Dati Finanziari

Organon Co (OGN)

Organon Co Stock (OGN) Company Profile

Organon Co Stock (OGN) Upgrades & Downgrades

Organon Co Borsa (OGN) Ultime notizie

Organon & Co. (NYSE:OGN) Sees Unusually-High Trading VolumeHere's Why - MarketBeat

Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance

Relative Strength Alert For Organon - Nasdaq

Organon updates outlook as FDA delays VTAMA label expansion - MSN

Organon reports FDA extension of target action date of review of Vtama sNDA - TipRanks

Organon’s VTAMA Cream FDA Review Extended to 2025 - TipRanks

Organon stock on watch as FDA delays VTAMA label (OGN:NYSE) - Seeking Alpha

FDA extends Organon's VTAMA cream review to March 2025 - Investing.com

Organon & Co (OGN) Stock Price Down 6.38% on Nov 4 - GuruFocus.com

Organon's SWOT analysis: stock outlook amid VTAMA potential and biosimilar growth - Investing.com UK

Organon & Co. (NYSE:OGN) Trading Down 4.4%Should You Sell? - MarketBeat

The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts - Simply Wall St

Organon China’s License and Supply Agreement with Shanghai Bao Pharmaceuticals - Global Legal Chronicle

(OGN) Technical Pivots with Risk Controls - Stock Traders Daily

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28 - Yahoo Finance

Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - MSN

Private Management Group Inc. Has $36.23 Million Holdings in Organon & Co. (NYSE:OGN) - MarketBeat

FDA accepts Organon BLA for Prolia/Xgeva biosimilar - MSN

Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023) - Yahoo Finance

Organon & Co. (NYSE:OGN) to Issue $0.28 Quarterly Dividend - MarketBeat

Organon & Co (OGN) Shares Up 5.61% on Oct 31 - GuruFocus.com

Organon: Q3 Earnings Snapshot - The Advocate

Organon & Co. Reports Strong Third Quarter 2024 Results - TipRanks

Organon Co earnings missed by $0.03, revenue topped estimates - Investing.com Australia

Organon (OGN) Q3 Earnings and Revenues Beat Estimates - MSN

Earnings call: Organon announced a revenue of $1.6 billion - Investing.com

Earnings call: Organon announced a revenue of $1.6 billion By Investing.com - Investing.com UK

Organon Reports Results for the Third Quarter Ended September 30, 2024 - BioSpace

Organon & Co Q3 2024 Earnings: EPS Soars to $1.38, Revenue Hits $1.582 Billion, Surpassing Estimates - GuruFocus.com

Organon & Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Organon Q3 2024 Earnings Preview: Dermavant purchase in focus - MSN

FDA accepts Henlius and Organon's biosimilar application By Investing.com - Investing.com South Africa

Organon Q3 2024 Earnings Preview: Dermavant purchase in focus (NYSE:OGN) - Seeking Alpha

FDA accepts Organon BLA for Prolia/Xgeva biosimilar (NYSE:OGN) - Seeking Alpha

FDA accepts Henlius and Organon's biosimilar application - Investing.com

Dermavant acquisition expands Organon’s dermatology portfolio - MSN

Organon Completes Acquisition of Dermavant - citybiz

Organon completes Dermavant Sciences acquisition - Investing.com

Organon completes Dermavant Sciences acquisition By Investing.com - Investing.com UK

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - StockTitan

Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance

Organon & Co. (NYSE:OGN) Short Interest Up 28.2% in October - MarketBeat

Do Options Traders Know Something About Organon (OGN) Stock We Don't? - MSN

Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline - Yahoo Finance

Organon & Co trades in the red for seven straight sessions - MSN

Organon & Co. (OGN) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 - Benzinga

Organon (Thailand) Ltd. promotes health and elevates women’s quality of life, creating change at the WEPs Awards 2024 - Nation Thailand

Organon (OGN) Dips More Than Broader Market: What You Should Know - Yahoo Finance

YieldBoost Organon From 6.4% To 11.4% Using Options - Nasdaq

With 80% institutional ownership, Organon & Co. (NYSE:OGN) is a favorite amongst the big guns - Simply Wall St

Organon Co Azioni (OGN) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a OGN